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Abstract
Introduction—RTOG-0937 is a randomized phase-II trial evaluating 1-year OS with PCI or PCI 
plus consolidative radiation therapy (cRT) to intra-thoracic disease and extracranial metastases for 
ED-SCLC.
Methods—Patients with 1–4 extracranial metastases were eligible after CR or PR to 
chemotherapy. Randomization was to PCI or PCI+cRT to the thorax and metastases. Original 
stratification included PR vs CR after chemotherapy and 1 vs 2–4 metastases; age < 65 vs ≥ 65 
was added after an observed imbalance. PCI was 25GY/10 fractions. cRT was 45GY/15 fractions. 
To detect an OS improvement from 30% to 45% with a 34% hazard reduction (HR=0·66) under a 
0.1 type-1 error (1-sided) and 80% power, 154 patients were required.
Results—Ninety-seven patients were randomized between March, 2010 and February, 2015. 
Eleven patients were ineligible (nine PCI, two PCI+cRT), leaving 42 randomized to PCI and 44 to 
PCI+cRT. At planned interim analysis the study crossed the futility boundary for OS and was 
closed prior to meeting accrual target. Median follow-up was 9 months. One-year OS was not 
different between the groups: 60.1% [95% CI: 41.2–74.7%] for PCI and 50.8% [95% CI:34.0–
65.3%] for PCI+cRT (p=0.21). Three and 12-month rates of progression were 53.3% and 79.6% 
for PCI, and 14.5% and 75% for PCI+cRT. Time to progression favored PCI+cRT, HR=0.53 (95% 
CI: 0.32–0.87, p=0.01). One-patient in each arm had Grade-4 therapy related toxicity and one had 
Grade-5 therapy related pneumonitis with PCI+cRT.
Conclusions—OS exceeded predictions for both arms. Consolidative RT delayed progression 
but did not improve 1-year OS.
Keywords
Small cell lung cancer; extensive disease; thoracic radiation therapy; PCI; oligometastases
Introduction
SCLC comprises approximately 13% of lung cancers diagnosed in the United States. The 
majority of patients with SCLC have metastatic disease.1 Primary therapy for ED-SCLC is 
4–6 cycles of platinum-based chemotherapy followed by PCI in select patients. Although 
response rates to chemotherapy are high at 60–70%, time-to-progression and median 
survival are modest (4–6 months and < 10 months, respectively).1,2 Response and 
improvement in survival is limited for second-line chemotherapy, particularly if progression 
is within 30–90 days.3,4 PCI has been shown to decrease brain metastases and improve 1-
year OS in patients that respond to chemotherapy.5 The use of consolidative thoracic 
radiation for ED-SCLC remains controversial even though it has been shown to improve 
survival and locoregional control in both prospective randomized trials6,7 and retrospective 
reviews.8,9
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RTOG-0937 was designed to address a select patient population with oligometastitc small 
cell lung cancer (1–4 distant metastases) with consolidative RT to the locoregional thoracic 
disease and active sites of metastases after chemotherapy. The underlying hypothesis was 
that delaying progression of disease with radiation therapy will delay progression and 
improve overall survival in this favorable patient population.
We conducted a randomized phase-II trial designed to evaluate PCI alone or PCI and 
consolidative RT (PCI+cRT) to intrathoracic disease and limited extracranial metastases in 
patients with oligometastatic small cell lung cancer.
Materials and Methods
Patient selection
NRG Oncology/RTOG 0937 is a two-arm randomized phase-II study designed to assess 
whether the use of cRT in addition to PCI (PCI+cRT) would improve OS compared to PCI 
alone for patients with ED-SCLC. Protocol approval was received from the Institutional 
Review Board at each study site. Informed consent was obtained from each patient prior to 
participation. Patients were randomly assigned to PCI or PCI+cRT to the intrathoracic 
disease and residual metastases. Eligible patients had pathologically proven SCLC without 
brain metastases and with 1–4 extracranial metastases at diagnosis based on CT scan of the 
chest/abdomen and bone scan or PET/CT. Brain imaging was not required prior to 
chemotherapy in the absence of symptoms but was required prior to randomization. Eligible 
patients had PR or CR to 4–6 cycles of platinum based chemotherapy in a minimum of one 
site of disease and no evidence of progression at any site. Restaging was required within 
eight weeks of study entry. Imaging included CT of the chest/abdomen or PET/CT, bone 
scan or PET, and MRI of the brain (or CT if MRI was contraindicated). Other eligibility 
criteria included Zubrod PS 0–2, serum ALT and AST within 2.5×ULN and bilirubin 
<1.5×ULN within one week prior to study entry for patients with liver metastases, serum 
creatinine < 1.5×ULN for patients with renal or peri-renal metastases, absolute neutrophil 
count ≥ 1,000 cells/mm3, platelets ≥ 75,000 cells/mm3 and hemoglobin ≥ 8 g/dl.
Treatment
All patients were to receive 25Gy PCI at 2.5Gy/fraction. In Arm 2, thoracic radiation 
therapy to primary and involved regional nodes was required for all patients unless they had 
had palliative radiation therapy to the primary at diagnosis. Radiation was delivered to post-
chemotherapy volumes including the site of the primary and involved nodal regions at 
diagnosis. Metastases were treated if they did not have a CR to chemotherapy. The 
recommended radiation dose to all extracranial sites was 45Gy delivered in 15 daily 
fractions of 3Gy. 30–40Gy was acceptable if dose reduction was necessary to meet normal 
tissue dose constraints. It was recommended that PCI be started concurrently with cRT 
although sequential therapy was allowed at the discretion of the treating physician.
Patients were evaluated after therapy at two weeks, one, two, six, nine, and 12 months, every 
six months for 2–3 years, then annually. CT of the chest/abdomen or PET/CT and brain 
imaging were required at each visit starting at two months.
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Statistical Analysis
The study was designed to detect a 33.7% relative reduction in the risk of death (HR, 0.663) 
in the PCI+cRT as compared with PCI alone, at the significance level of 0.1 (1-sided) with 
80% power. Based on the above, a total of 112 events and a sample size of 146 were 
required. Adjusting for an ineligibility or insufficient follow-up rate of up to 5%, the final 
targeted accrual was 154. Two interim analyses and a final analysis were planned for early 
stopping for efficacy and futility when 37 and 75 deaths from both arms were observed. The 
efficacy testing was based on the power family of test 10 with ∆=0, and the futility testing 
boundary was based on Rule C (at a nominal significance level of 0.005) as proposed by 
Freidlin and Korn.11 NRG Oncology/RTOG Data Monitoring Committee (DMC) oversaw 
the interim monitoring. Patients were equally randomized into the two arms, based on 
Zelen’s allocation scheme and stratified by response to treatment (CR vs. PR), number of 
metastases (1 vs. 2–4), and age (<65 vs. ≥65, added on July 15, 2014). Age was added as a 
stratification factor at the recommendation of the DMC when an unbalanced distribution 
between treatment arms was observed without knowledge of efficacy information.
All outcome times were calculated from the date of randomization to the date of event or, if 
no event, the date of last follow-up. For OS, the event is death due to any cause. The Kaplan-
Meier method12 was used to estimate OS rates. For time to progression, the event was the 
first occurrence of recurrence/progression of pre-existing disease (regardless of prior 
response or treatment with RT) or development of new metastases. Death without failure 
was considered as a competing risk. Actual rates of time to progression were estimated using 
the cumulative incidence method13 by taking into account competing risks. The log-rank 
test14 was used to compare OS event rates between treatments. The Cox regression model15 
was used to compare the treatment differences. For time to progression, competing risk 
events (death without progression) were censored at the time of competing event per the 
cause-specific competing risks analysis method.16 Adverse events were evaluated using the 
NCI CTCAE v4.0.
Results
The study opened to accrual March 18, 2010 and closed February 27, 2015. A planned 
interim analysis indicated that the study crossed the futility boundary for the primary 
endpoint and was closed prior to meeting the accrual target of 154 patients. The final 
analysis was performed in August 2015 with a median follow-up of nine months, based on 
all data received at NRG Oncology Statistics and DMC through July 15, 2015. 97 patients 
were randomized from 57 participating sites. Eleven patients were ineligible and excluded 
from analysis, nine patients randomized to PCI and two to PCI+cRT. Reasons for 
ineligibility included failure to receive protocol therapy (two), inability to confirm eligibility 
(two), testing completed outside the required time frame (four), brain metastases (one), 
chemotherapy completed > eight weeks from study entry (one), and platelet count outside of 
required range (one). 86 patients, 42 randomized to PCI and 44 to PCI+cRT, were included 
in the analysis (Figure 1).
Pretreatment characteristics were evenly distributed with the exception of age (Table 1). 
54.5% of patients randomized PCI+cRT and 38.6% to PCI arm were ≥ 65 (p=0.03). CR to 
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chemotherapy (prior to study entry) in the primary lung tumor was 15.9% and PR 68.1%. 
36% of patients had one metastasis, and 36%, 15.1% and 12.8% had two, three and four 
metastases. The median time from diagnosis to start of radiation was 22 weeks for each 
group. Median time from end of chemotherapy to start of radiation was 5.9 weeks and 6.9 
weeks for PCI and PCI+cRT.
Among the PCI+cRT patients, two (4.5%) did not have TRT. Treating physicians withheld 
radiation due to CR (1) and anticipated poor tolerance (1). Of the patients treated with cRT, 
90.5% received thoracic radiation per protocol (30–45Gy). Two patients received less than 
30Gy (22.5Gy and 24Gy) and two patients received > 45Gy (50 and 65Gy). 95.3% of all 
patients received PCI per protocol.
At the time of this analysis, 51 deaths, including 22 with PCI, and 29 with PCI+cRT, were 
reported. The one-year OS rates were 60.1% [95% CI: 41.2–74.7%] for PCI and 50.8% 
[95% CI: 34.0–65.3%] for PCI+cRT (Figure 2). Median Survival was 15.8 months for PCI 
and 13.8 months for PCI+cRT. The two-sided log-rank test p-value was 0.21, and the 
unadjusted HR is 1.44 (HR favors PCI, 95% CI: 0.82–2.53). The majority of patients died of 
disease progression (76.5%). Patients with CR to chemotherapy at all sites of disease 
appeared to have better survival outcome than those with PR (any site), with a HR of 2.1 
(HR favors CR, 95% CI: 0.97, 4.56) and p=0.06. Due to the limited sample of patients with 
CR (all sites), PCI (10) and PCI+cRT (7), it was not possible to determine if PCI+cRT had a 
differential treatment effect over PCI alone between CR and PR patients.
There were 32 patients with progression in the PCI arm, and 31 in the PCI+cRT arm. The 
three-month and one-year rates of any progression were 53.3% [95% CI: 36.3–67.7] and 
79.6% [95% CI: 60.6–90.2] for PCI, and 14.5% [95% CI: 5.8–27.0] and 75.0% [95% CI: 
57.9–86.0] for PCI+cRT. The difference in the distribution of time to progression is 
statistically significant (log-rank test p-value 0.01) with a hazard ratio 0.53 (HR favors PCI
+cRT, 95% CI: 0.32, 0.87) (Figure 3). There were only two and four deaths without 
progression with PCI and PCI+cRT, respectively. Patients with CR (all sites) had a longer 
time to progression than those with PR (any site), HR of 2.08 (95% CI: 1.04, 4.17) and 
p=0.04. Median Progression Free Survival was 2.9 months [95% CI: 2.4, 3.7] for PCI and 
4.9 months [95%CI: 3.4, 6.0] for PCI+cRT, p-value 0.0148.
First site of failure was in the sites present at diagnosis in 25 (78.1%) patients with PCI and 
13(41.9%) with PCI+cRT (Table 2). First site of failure at sites of locoregional disease was 
reported in 20 (62.5%) and 8(25.8%) of patients with PCI and PCI+cRT. New sites of 
disease (not present at diagnosis) were reported in 10 (31.3%) of the 32 patients with PCI 
and 19 (61.3%) of the 31 patients with PCI+cRT arm who progressed. First site of failure 
occurred outside of radiation fields in 17 (54.8%) patients with PCI+cRT. In patients treated 
with PCI+cRT there were ten (32.3%) first failures in the consolidative radiation fields 
(other than brain), and four (12.9%) first failures in the brain only. One-year cumulative 
incidence of brain metastases was 17% [95% CI: 6.6–40.2] and 18.5% [95% CI: 8.5–37.6] 
with PCI and PCI+cRT. Brain was a component of first failure in six (19.4%) of the 31 
patients with failures with PCI+cRT and in none of the 32 patients with PCI only.
Gore et al. Page 5
J Thorac Oncol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Grade-3 or greater adverse events regardless of attribution to protocol therapy occurred in 
ten (23.8%) patients with PCI and 16 (36.4%) with PCI+cRT, p=0.24. Grade-3 or greater 
toxicity attributed to therapy was reported in four (9.5%) patients with PCI and 11 (25%) 
with PCI+cRT. Grade-3 toxicity with PCI+cRT included decreased blood counts, esophageal 
symptoms, tachycardia, fatigue and respiratory symptoms. Grade-4 dyspnea and tracheal 
stenosis was reported in one (2.4%) patient with PCI only and no Grade-5 toxicity attributed 
to therapy with PCI. Two (4.5%) patients had Grade-4 and one (2.3%) Grade-5 toxicity 
attributed to treatment with PCI+cRT. Grade-4 toxicity included hypoxia and respiratory 
failure during treatment, and decreased platelets at 12 days post therapy. Grade-5 
pneumonitis attributed to therapy was reported in one patient with PCI+cRT. This patient 
received 42Gy to the chest with 37% of the lung receiving 20Gy or more, exceeding 
protocol normal tissue dose constraints (Table 3).
Discussion
Thoracic radiation and PCI have been shown to decrease the incidence of locoregional 
failures and brain metastases and improve survival in both LD-SCLC17,18 and ED-SCLC.5–7 
Although multimodality therapy for LD-SCLC is standard of care, it remains controversial 
for ED-SCLC. Patients with good response to chemotherapy and limited metastatic disease 
are the most likely patients with ED-SCLC to benefit from multimodality therapy. NRG 
Oncology RTOG 0937 was conducted to assess a potential survival advantage of 
consolidative extracranial irradiation in patients with oligometastatic ED-SCLC. Although a 
negative trial, there were several important findings: the first site of failure after 
chemotherapy is likely to be in sites of presenting disease; radiation therapy to these sites 
alters failure patterns; late radiation therapy without concurrent chemotherapy is not durable; 
and, oligometastatic ED-SCLC survival approaches that of LD SCLC. Ineffective radiation 
dose and schedule, advanced age and an imbalance in disease burden in the two groups all 
likely contributed to lack of survival advantage with consolidative radiation therapy in this 
trial.
Survival
Early randomized studies showed a survival advantage with thoracic radiation in addition to 
chemotherapy for LD-SCLC.19,20 These early LD-SCLC studies did not include the routine 
use of CTs and were conducted before the era of PET/CT and MRIs, therefore many patients 
likely had unrecognized ED-SCLC. The routine use of PET/CT has been shown to increase 
stage in 8–18% of patients.21,22 Thoracic radiation for ED-SCLC was supported by the 
Jeremic trial reported in 1999 which showed a survival advantage in patients with ED-SCLC 
treated with thoracic radiation. Despite compelling data, the routine use of thoracic radiation 
in ED-SCLC has not been regarded as standard of care. However, many clinicians have 
selectively used thoracic radiation and have published outcomes in several retrospective 
reviews published since the initiation of the current trial. These retrospective reviews and 
database analyses have shown improvement in survival with thoracic radiation (Table 4).6–9
The CREST trial, conducted in the Netherlands and the United Kingdon, was conducted 
during the same time as the current trial. It included 495 patients with ED-SCLC randomly 
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assigned to PCI or PCI and thoracic radiation (30Gy/10 fractions) after response to 
chemotherapy. The number of metastases was not limited. OS at one year was the primary 
endpoint. One-year OS was not different between the two groups with 33% (95% CI 27–39) 
for thoracic radiation versus 28% (95% CI 22–34) for observation (hazard ratio [HR] 0.84, 
95% CI 0.69–1.01; p=0.066). However, secondary analysis of two-year OS showed 
improvement with thoracic radiation, 13% (95% CI 9–19) versus 3% (95% CI 2–8; 
p=0.004). Toxicity was acceptable with 2% and 1.2% Grade-3 esophageal and pulmonary 
toxicity.6
Additional analysis of CREST to identify patients who may have benefitted most from 
thoracic radiation showed that thoracic radiation led to a significant difference in overall and 
progression-free survival in patients who had residual intrathoracic disease after 
chemotherapy. In these patients, the difference in OS was statistically significant (p=0.03; 
HR 0.81; 95% CI: 0.66–0.98; stratified). They concluded that thoracic radiation should be 
offered to patients with a good response or PR after chemotherapy, but not those with thorax 
CR.23 There were too few patients in 0937 to perform this analysis.
The trial published by Jeremic et al in 1999 supported thoracic radiation for EDSLC in 
patients with at least a PR to locoregional disease and a CR to extrathoracic sites with 
chemotherapy.7 Similar to 0937, the majority of patients had one to two sites of metastases 
at diagnosis, although this was not a requirement. Unlike NRG Oncology RTOG 0937, 
patients with good response to first 3 cycles of chemotherapy received high dose radiation 
therapy to the primary locoregional disease only with concurrent chemotherapy. Patients 
were treated initially with three cycles of cisplatin and etoposide. Those with a CR or PR 
locally and a CR at distant sites were treated with two cycles of carboplatin and etoposide +/
− concurrent hyperfractionated RT to the thorax (54Gy/36 fractions over 18 days). Both 
groups received PCI. Median Survival (17 months versus 11 months, p=0.041), five-year 
survival (9.1% versus 3.7%, p=0.041), and median time to local recurrence (30 versus 22 
months, p=0.062) were improved in the RT group. The investigators did not describe a 
difference between patients with and without residual disease in the chest after 
chemotherapy. Distant metastatic rate remained high in both groups. The pattern of failure 
relative to initial pattern of distant disease was not described.7
An important finding in NRG Oncology RTOG 0937 is that the median OS (15.8 months) 
and one-year OS (60.1% 95%CI: 41.2, 74.7) in the PCI arm in 0937 exceeded what was 
predicted with chemotherapy and PCI for ED-SCLC. For comparison, the median survival 
with chemotherapy and PCI was 15.8 months compared to 8 months in the CREST trial. 
Both of these trials calculated survival from randomization, which was after 4–6 cycles of 
chemotherapy and restaging. In 0937 the median time from diagnosis to start of radiation 
was greater than four months. The medians survival in the Jeremic trial with chemotherapy 
and PCI alone for patients with CR to distant sites was 11 months from randomization which 
was prior to starting chemotherapy. Additionally, the outcome of 0937 compares favorably 
to the intergroup trial for LD-SCLC with concurrent RT to 45Gy at 1.8Gy daily fractions or 
1.5Gy twice daily fractions with medians survival from randomization prior to 
chemotherapy of 19 and 23 months respectively.24
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The design of 0937 intentionally included a favorable patient population with 
oligometastases by rigorous staging at diagnosis and after chemotherapy. Perhaps a more 
appropriate treatment for this patient population with low volume systemic disease is early 
radiation concurrent with cycle three or four of chemotherapy in patients with a favorable 
response to cycles one and two of chemotherapy followed by PCI, similar to the Jeremic 
trial.
Concurrent chemotherapy and radiation has been shown to be superior to sequential 
therapy.17 The importance of the early use of RT in LD-SCLC was demonstrated in the 
National Cancer Institute of Canada Clinical Trials Group in 1993.25 Patients were 
randomized to begin thoracic radiation on week 3 or 15 of chemotherapy. Patients without 
progressive disease received PCI following chemotherapy and radiation. Progression free 
survival (p=0.036) and OS (p=0.008) were superior with early thoracic radiation. 
Additionally patients with late radiation had a higher risk of brain metastases.25 A 
subsequent meta-analysis was undertaken by De Ruysscher et al to identify time factors for 
combined chemotherapy and radiotherapy that may influence OS.26 The time from first day 
of chemotherapy to last day of RT (Start of chemotherapy to End of Radiation (SER)) was 
the most important predictor of outcome. There was a significantly higher five-year survival 
rate in the shorter SER arms (relative risk [RR] = 0.62; 95% CI, 0.49 to 0.80; P =.0003), 
which was more than 20% when the SER was less than 30 days (upper bound of 95% CI, 90 
days).20 For comparison the SER for 0937 was well over 150 days.
Failure Patterns
Brain failures are well described and reported, although extracranial failure patterns after 
chemotherapy have not been reported in detail. It is intuitive that the most likely site of 
failure after chemotherapy for ED-SCLC is in areas of measurable disease at diagnosis, 
particularly sites without at CR to chemotherapy. In the landmark trial showing an 
improvement in 1 year overall survival with PCI in patients with ED-SCLC published by 
Slotman et al, the chest was the most likely site of progression.5 Persistent intrathoracic 
disease was present in 75% of patients after chemotherapy and approximately 90% had 
intrathoracic progression in the first year. The CREST trial, evaluating thoracic radiation 
therapy following chemotherapy was a natural follow up to this trial.6 Unlike the CREST 
trial, NRG Oncology RTOG 0937 included consolidative RT to distant metastases in 
addition to thoracic radiation and is the first study to evaluate outcomes and report failure 
patterns in patients with oligometastatic ED-SCLC.
Patients on 0937 were more likely to fail in in sites of disease present at diagnosis. Fewer 
patients in the PCI+cRT arm had their locoregional disease as a component of first failure 
(25.8% vs 62.5%). Progression at presenting sites of disease was higher with PCI (78.1%) 
than PCI+cRT (41.9%). Similar to 0937, patients on the CREST trial had lower isolated 
intrathoracic progression of 19.8% with thoracic radiation compared 46% in the observation 
arm (p<0.0001).6 Likewise, local recurrence free survival in the Jeremic trial at five years 
was 20% with RT and 8.1% with chemotherapy only (p=0.062).7 Early concurrent 
chemotherapy and high dose radiation therapy in the Jeremic trial likely contributed 
favorable local recurrence free survival. An unexplained finding in the current trial was more 
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new sites of disease and first-failures in the brain with PCI+cRT compared to PCI alone. 
There was not a clear explanation for this based on site, volume and number of metastases. 
Higher brain failures and new sites of disease suggests that there was an unaccounted for 
imbalance in systemic disease burden decreasing the likelihood of seeing a survival 
advantage with PCI+cRT.
Although consolidative radiation to locoregional disease and residual metastases after 
chemotherapy delayed progression at 3 months, this benefit was not durable. The 3-month 
rate of progression was 53.3% with PCI and only 14.5% with PCI+cRT, although by 1 year 
the progression rates were not different at 79.6% and 75%, respectively. A more aggressive 
course of radiation therapy would have likely resulted in a more durable response. PCI 
remains controversial in the treatment ED-SCLC despite a survival advantage at 1 year 
demonstrated by Slotman et al5 and advantages of PCI in early trials with subset analysis of 
patients with extensive disease.18 Adding to this controversy is a recent Japanese trial which 
did not show a survival benefit with PCI.27 PCI has consistently been shown to be effective 
for decreasing brain failures although it is not completely clear which patients will derive a 
survival benefit. Extent of disease at diagnosis, response to chemotherapy and 
immunotherapy are important considerations. Treatment of active extracranial disease is 
likely to also play an important role as active extracranial disease will continue to seed the 
brain after PCI.
Toxicity
NRG Oncology 0937 was closed early due to a futility analysis showing that it was unlikely 
there would be a survival advantage in the study arm. Unfortunately, unofficial 
communications and discussions have suggested that there was excess toxicity on this trial.
Toxicity in 0937 was as anticipated with the therapy delivered (Table 3). Grade 3+ toxicity 
was 23% for PCI and 36% for PCI+cRT, p=0.24. Grade-4 and 5 toxicity included 
hematologic and pulmonary toxicity. There was one death attributed to protocol therapy. 
This patient had radiation-induced pneumonitis. The radiation dose to normal lung exceeded 
dose constraints required by protocol. This emphasizes the importance of careful attention to 
minimizing normal tissue dose exposure to radiation. Toxicity in 0937 compares favorably 
to toxicity reported other trials evaluating thoracic RT for ED-SCLC and LD-SCLC. Jeremic 
et al reported 20% Grade-3 and 7% Grade-4 esophageal toxicity and 5% Grade-3 
bronchopulmonary toxicity with radiation and similar to CREST.6,7 Future studies should 
encourage or require use RT techniques such as Intensity Modulated Radiation Therapy 
(IMRT) and Stereotactic Body Radiation Therapy (SBRT) to minimize dose to normal 
tissues including bone marrow to minimize hematologic toxicity and improve tolerance to 
systemic therapy.
Conclusion
Patients with ED-SCLC represent a diverse patient population with a wide range of 
anticipated outcomes. There is not one appropriate treatment regimen for all patients. This 
study was the first to prospectively evaluate the favorable population with oligometastatic 
SCLC. Consolidation radiation therapy delayed progression and altered failure patterns in 
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this population. Toxicity was as anticipated with the therapy delivered and similar to 
published data. The lack of benefit seen with PCI+cRT in this very favorable cohort of 
patients with ED-SCLC may be due to lack of optimal timing, dose and fractionation of 
radiation therapy. This study has demonstrated that this favorable subpopulation of patients 
with ED-SCLC has OS similar to patients with LD-SCLC. Future trials for this population 
should focus on timing, dose, and fractionation of radiation therapy delivery.
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Figure 1. 
CONSORT Flow Diagram
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Figure 2. 
Overall Survival
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Figure 3. 
Time to progression
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Table 1
Demographics
Patient or Tumor Characteristic
PCI
(n=42)
n (%)
PCI and Consolidative
RT
(n=44)
n (%)
Total
(n=86)
n (%)
Age
 Median (Range) 60.5 (47 – 81) 66 (35 – 86) 63 (35 – 86)
 < 65 30 (71.4%) 20 (45.5%) 50 (58.1%)
 ≥ 65 12 (28.6%) 24 (54.5%) 36 (41.9%)
Gender
 Male 18 (42.9%) 21 (47.7%) 39 (45.3%)
 Female 24 (57.1%) 23 (52.3%) 47 (54.7%)
Zubrod Performance Status
 0 21 (50.0%) 18 (40.9%) 39 (45.3%)
 1 21 (50.0%) 25 (56.8%) 46 (53.5%)
 2 0 (0.0%) 1 (2.3%) 1 (1.2%)
Response to initial treatment
(locoregional/metastases)
 CR/CR 10 (23.8%) 7 (15.9%) 17 (19.8%)
 CR/PR 5 (11.9%) 6 (13.6%) 11 (12.8%)
 PR/PR or Stable 27 (64.3%) 31 (70.5%) 58 (67.4%)
Number of metastatic lesions
 1 17 (40.5%) 14 (31.8%) 31 (36.0%)
 2–4 25 (59.5%) 30 (68.2%) 55 (64.0%)
Lesion locations†
 Head and neck 4 (9.5%) 2 (4.5%) 6 (7.0%)
 Gastrointestinal 1 (2.4%) 1 (2.3%) 2 (2.3%)
 Liver 10 (23.8%) 10 (22.7%) 20 (23.3%)
 Renal 1 (2.4%) 0 (0.0%) 1 (1.2%)
 Adrenal 6 (14.3%) 11 (25.0%) 17 (19.8%)
 Bone 11 (26.2%) 8 (18.2%) 19 (22.1%)
 Distant lymph nodes 13 (31.0%) 10 (22.7%) 23 (26.7%)
 Skin 0 (0.0%) 1 (2.3%) 1 (1.2%)
 Contralateral lung 3 (7.1%) 6 (13.6%) 9 (10.5%)
 Other location 13 (31.0%) 21 (47.7%) 34 (39.5%)
†
Patients may have more than one site; percentages will not add to 100.
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Table 2
Failure Patterns
PCI
(n=32)
n (%)
PCI and Consolidative
RT
(n=31)
n (%)
First failure at site of disease present at diagnosis 25 (78.1%) 13 (41.9%)
Locoregional disease as first failure 20 (62.5%) 8 (25.8%)
First failure brain 0 (0.0%) 6 (19.4%)
Failure at any time at new site 10 (31.3%) 19 (61.3%)
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Table 3
Grade 3+ toxicity related to therapy.
Toxicity PCIN=42
PCI+cRT
N=44
Anemia 1  1  
Tachycardia 0  1  
Retinal Detachment 0  1  
Gastrointestinal* 1  5  
Fatigue 1  3  
Lung Infection 0  2  
Metabolism# 0  3  
Muscle Weakness 0  1  
Nervous System 1  1  
Respiratory (grade 3) 0  2  
Respiratory (Grade 4) 1  1  
Respiratory (Grade 5) 0  1  
Hypotension 0  2  
Decreased Platelets
(grade 4) 0  1  
Other** 1  4  
*
Diarrhea, dyspepsia, dysphagia, esophagitis, nausea
#
Hyperglycemia, anorexia, dehydration
**
Decreased lymphocytes, decreased white blood cells
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